Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma

BACKGROUND: Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. METHODS: This retrospective observational study utilized data from the US Oncology Network iKnowMed electronic healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Samlowski, Wolfram, Robert, Nicholas J., Chen, Liwei, Schenkel, Brad, Davis, Catherine, Moshyk, Andriy, Kotapati, Srividya, Poretta, Tayla, Weber, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939122/
https://www.ncbi.nlm.nih.gov/pubmed/35880244
http://dx.doi.org/10.1002/cam4.5061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939122/
https://www.ncbi.nlm.nih.gov/pubmed/35880244
http://dx.doi.org/10.1002/cam4.5061

Ejemplares similares